HITIQ Raises $2.09M Total, Issues 9.4M Shares in Shortfall Offer
HITIQ Limited has issued over 9.4 million shares and nearly 4.7 million options under its shortfall offer, raising $206,960 and progressing its ongoing rights issue. The company also clarified a duplicate filing and updated its issued capital structure.
- Issued 9.4 million shares and 4.7 million attaching options under shortfall offer
- Raised $206,960 from shortfall placement, total funds raised now $2.09 million
- Remaining shortfall balance stands at approximately $1.51 million
- Clarified duplicate Appendix 2A filing from June 2025
- Updated issued capital totals 469 million shares and 47.5 million options
Progress on Capital Raising
HITIQ Limited (ASX – HIQ), a pioneer in concussion management technology, has taken another step forward in its capital raising efforts by issuing 9,407,275 new ordinary shares alongside 4,703,640 free attaching options under its shortfall offer. This placement forms part of the company's pro-rata non-renounceable rights issue announced earlier in May 2025.
The shortfall placement has generated $206,960 in additional funds, contributing to a total of approximately $2.09 million raised through the rights issue and associated placements to date. Despite this progress, a remaining shortfall balance of around $1.51 million remains to be placed, which HITIQ intends to address with further announcements in the coming days.
Clarification and Capital Structure Update
Alongside the capital raise update, HITIQ clarified a duplicate Appendix 2A filing lodged in June 2025, which investors are advised to disregard. The company provided a refreshed summary of its issued capital, now standing at 469,105,189 ordinary shares and 47,495,935 options, reflecting the recent placements.
The updated capital structure includes various classes of securities such as options expiring in 2025 and 2028, convertible notes, performance rights, and employee shares, underscoring the complexity of HITIQ’s capital base as it balances growth funding with shareholder interests.
Market and Strategic Implications
HITIQ’s ongoing capital raising is critical to supporting its innovative concussion management technology platform, PROTEQT, which serves elite and community sports globally. The fresh capital will likely bolster product development, market expansion, and operational resilience amid competitive pressures in the sports technology sector.
Investors will be watching closely for the company’s next moves on placing the remaining shortfall, as well as any strategic updates that might accompany further capital injections. The dilution impact from new shares and options issuance will also be a key consideration for existing shareholders assessing the value proposition of HITIQ’s growth trajectory.
Bottom Line?
HITIQ’s capital raise momentum continues, but the final placement of the remaining shortfall will be pivotal for its next growth phase.
Questions in the middle?
- How will HITIQ allocate the proceeds from the remaining shortfall placement?
- What impact will the ongoing dilution have on earnings per share and shareholder value?
- Will HITIQ announce any strategic partnerships or product developments alongside future capital raises?
